Healthcare & Life Sciences

Mammalian Cell SHMT2 Reduction for Protein Production

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.

CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation

USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs. The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.

CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA

The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.

Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment

USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

Genentech Modified CHO Cells for Therapeutic Protein Production

USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.

Neurocatheters, Systems, and Methods of Use

USPTO published patent application US20260097183A1 for neurocatheter technology. The patent covers catheters with proximal and distal portions having different stiffness ratios (proximal portion stiffer than distal by at least 10x). The catheter is configured for intracranial vessel access without requiring a guide sheath. Inventors: Paul De Lipski, John Miller, Tony M. Chou, Stephanie Sharpe, Christina Van. Filing date: 2025-10-03.

Sealing Cap for Syringe Tip Patent Application US20260097170A1

USPTO published patent application US20260097170A1 by inventor Mirhac Dinc for a sealing cap for a syringe tip. The application, filed July 28, 2023, describes a housing with a connection portion and an insert-engagement portion containing a sealing insert with tip-engagement and housing-engagement portions. The public notice period allows interested parties to review the invention before potential grant.

MITAKA HDGS Needleless Syringe, Multiple Doses, Apr 09

MITAKA HDGS Needleless Syringe, Multiple Doses, Apr 09

Monitoring Device with Optical and Vibration Sensors for Medicament Delivery

The USPTO published patent application US20260097169A1 for a monitoring device designed to attach to medicament delivery devices. The device uses an optical sensor and vibration sensor to detect when a dose activation element is manually operated and correlates sensor data to confirm correct dose setting. The inventors are William Cirillo. The application was filed on May 27, 2025.

Access Vascular Inc - Gradient Annealing Polymeric Catheters

USPTO published patent application US20260097181A1 for Access Vascular Inc covering gradient annealing methods for polymeric catheter components with spatially varying mechanical properties. The application claims methods for producing catheters with improved kink resistance by spatially varying annealing to balance patient comfort with insertion ease. Inventors include Daniel T. Donahue, Michael Bassett, and Matthew M. Mannarino.

Machine Proximate Nebulizer Respiratory Therapy System

The USPTO has published patent application US20260097172A1 for a machine proximate nebulizer respiratory therapy system. The application, filed on June 11, 2025, covers a nebulizer system with a cylindrical mixing chamber, impacting cap, and recirculation tube for delivering aerosolized medicaments in respiratory therapy. The invention aims to improve aerosol delivery efficiency by entraining aerosol into breathing gas and recirculating rain-out droplets.

Tip Cap for Medical Injection Device, US20260097171A1

USPTO published patent application US20260097171A1 for a tip cap designed to seal a fluid passageway in a medical injection device. The application, filed September 19, 2023, covers an elastomeric inner cap with a proximally extending skirt in sealing engagement with a medical container tip, enclosed within a rigid outer cap having a threaded portion. The invention classifies under CPC codes A61M 5/345 and related medical device categories.

Direct View Scleral Contact Lens for Laser Trabeculoplasty

The USPTO published patent application US20260096928A1 assigned to Ocular Instruments, Inc. covering a direct view scleral contact lens designed for use in direct selective laser trabeculoplasty (DSLT) procedures. The invention includes a lens body with an inferior light exit surface forming a compression annulus that contacts the patient's eye during laser treatment, plus a ring of alignment markers.

Micro Actuator for Inner Ear Injection and Sampling Surgery

USPTO published patent application US20260096931A1 for a micro actuator for inner ear injection and sampling surgery. The invention includes a microneedle puncture mechanism, driving and sensing module, high-precision linear driving module, end-effector mechanism module, endoscope camera module, and tension sensor for real-time monitoring. Inventors: He Zhang, Haiming Li, Jie Zhao. Filed January 16, 2025.

Covidien LP Dermal Patch for Wound Healing

Covidien LP filed patent application US20260096933A1 for a dermal patch system designed to support, protect, and medicate wounds during the healing process. The patch includes a support layer and medicament depot. The application was filed November 11, 2025, under application number 19386193.

Heated Hydrocolloid Patches For Skin Blemish Treatment

USPTO published patent application US20260096932A1 for a heated hydrocolloid skin patch with thermochromic temperature indicator, filed December 2, 2025. The invention comprises an outer barrier layer, a hydrocolloid layer, and thermochromic material that indicates when the patch reaches a predetermined temperature. The technology is applicable to skin blemish and wound treatment products.

Comfort Sleeve Patent For Male Incontinence

USPTO published patent application US20260096934A1 for a comfort sleeve designed for male incontinence. The device features a sleeve with outer and inner layers containing an absorbent material, with upper, lower, and contour compression zones each having elastic bands with varying elasticity to comfortably secure and shape the sleeve around the penis.

Cerebral Embolic Protection Selection Method For TAVI Procedures

USPTO published patent application US20260096795A1 for a cerebral embolic protection selection method for TAVI procedures. The invention determines whether to deploy a CEP device by retrieving and segmenting aortic valve images to identify plaque vulnerability, then evaluating blood flow dynamics to select appropriate protection. Inventors include Holger Schmitt, Michael Grass, Christian Haase, and others.

Methods to Reconstruct Bone and Joint Surfaces in Femorotibial and Patellofemoral Joint

USPTO published patent application US20260096890A1 assigned to Subchondral Solutions, Inc. for methods of bone and joint surface reconstruction in femorotibial and patellofemoral joints. The application covers therapeutic approaches to joint defects designed to restore biomechanical function without full joint replacement. The invention leverages subchondral bone health in treating mammalian joint conditions.

Elastic Member and Disposable Wearing Article Including Elastic Member

USPTO published patent application US20260096935A1 assigned to Daio Paper Corporation for an elastic member designed to create non-monotonous, appealing wrinkles when applied to disposable absorbent articles such as diapers. The invention includes a third joined portion row between first and second joined portion rows with intervals longer than the standard interval S1. The application (No. 19352087) was filed on October 7, 2025.

Adjustable Endobronchial Valve, Expandable Struts, Microfibers

Adjustable Endobronchial Valve, Expandable Struts, Microfibers

CMS Proposes 2-4% Medicare Advantage Payment Changes, Risk Adjustment Updates, Audit Focus for 2027

CMS has issued its Advance Notice and related rulemaking for Medicare Advantage (MA) and Part D programs for plan year 2027, projecting a net payment increase of approximately 2% to 4% depending on final rate-setting. The proposals advance revised Hierarchical Condition Categories (HCCs), continue efforts to reduce coding intensity, and expand Risk Adjustment Data Validation (RADV) audits with increased scrutiny of diagnosis reporting and supporting documentation.

DOJ Consolidates Health Care Fraud Enforcement Under New Division

The DOJ announced creation of the National Fraud Enforcement Division (NFED) on April 7, 2026, consolidating the Tax Section, Health Care Fraud Unit, and Market, Government, and Consumer Fraud Unit under Assistant Attorney General Colin McDonald. The NFED will coordinate fraud enforcement across federal, state, tribal, and local authorities targeting schemes against taxpayer-funded programs.

OIG Advisory Opinion 25-11 on Medical Product Discount Compliance

Foley & Lardner LLP analyzed OIG Advisory Opinion 25-11, which provides guidance on structuring discount arrangements for medical products under the federal Anti-Kickback Statute. The advisory opinion offers detailed guidance on permissible discount practices and the requirements of the discount safe harbor. The analysis notes that while failure to precisely meet safe harbor requirements does not automatically violate the AKS, such arrangements lose guaranteed protection and become subject to OIG's facts and circumstances analysis.

Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors for Cancer Treatment

USPTO published patent application US20260097019A1 disclosing trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors for treating cancer and inhibiting tumor growth and metastasis. Inventors: Kavitha Nellore and Subramanya Hosahalli. Application filed April 30, 2025.

Stable Amlodipine Oral Liquid Formulations for Hypertension and CAD Treatment

USPTO published patent application US20260097025A1 for stable amlodipine oral liquid formulations filed by inventors Scott Brauer and Gerold L. Mosher. The application covers formulations containing amlodipine for treating hypertension and Coronary Artery Disease (CAD), with CPC classifications in A61K therapeutic preparations. The application was filed on June 17, 2025, under application number 19240194.

Buprenorphine Depot Formulation Controlled-Release Matrix

USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix with an oxygen-containing organic solvent and at least 12% by weight buprenorphine or salts thereof. Inventors include Fredrik Tiberg, Ian Harwigsson, and Markus Johnsson. The application covers methods for pain management and opioid maintenance treatment.

Unit Oral Dose Compositions of Ibuprofen and Famotidine for Acute Pain and Heartburn Reduction

The USPTO published patent application US20260097023A1 for unit oral dose compositions combining ibuprofen (50-400 mg) and famotidine (3-20 mg) designed to treat acute pain while reducing the severity or risk of heartburn and upset stomach. The formulation specifies that famotidine must dissolve faster than ibuprofen within 45 minutes of administration. The application was filed on December 2, 2025, by inventor Bernard Schachtel.

Therapeutic Use of Aromatase Inhibitors and PARP Inhibitors for Treatment of Malignancies

USPTO published patent application US20260097020A1 covering methods for treating gliomas including glioblastoma using aromatase inhibitors such as letrozole, optionally combined with PARP inhibitors (olaparib, pamiparib, veliparib, or niraparib). The application was filed September 30, 2025 under application number 19345169. Inventors include Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, and Gary A. Gudelsky.

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Integrated Preparedness Plan Workshop, Seymour IN, April 13

The Indiana Department of Health announces an Integrated Preparedness Plan Workshop on April 13, 2026, from 10:00 AM to 2:00 PM at Redeemer Lutheran Church in Seymour, IN. The workshop aims to validate preparedness priorities, identify capability gaps, and incorporate lessons learned from real-world events. Intended audience includes Local Health Department Preparedness Coordinators, Healthcare Coalition Readiness and Response Coordinators, and other preparedness organizations.

Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides

The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents. This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.

Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA

The USPTO published patent application US20260096997A1 assigned to SISAF LIMITED, filed November 6, 2025. The application covers a composition for controlled release of nucleic acids such as short interfering RNA (siRNA) or messenger RNA (mRNA), comprising silicon nanoparticles comprising at least 50% by weight silicon, at least one amino acid, and at least one lipid. The CPC classifications indicate primary focus on pharmaceutical preparations (A61K) and therapeutic uses including ophthalmological applications (A61P 27/02).

Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics

The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.

Modified oHSV with HRG for Cancer Therapy

The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.

Herbal Medicine Extracts RM01 for Alzheimer's Treatment

The USPTO has published patent application US20260097090A1, filed September 26, 2023, and published April 9, 2026, covering herbal extract compositions for treating neurodegenerative diseases including Alzheimer's disease. The composition includes extracts from Ophiopogon japonicus, Barbary Wolfberry, Rhizoma Acori tatarinowii, and Codonopsis pilosula. This is a patent application publication, not a granted patent, and does not confer any regulatory approval for the claimed treatments.

Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment

USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.

Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells

USPTO published patent application US20260097131A1 titled 'Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells.' The application (filed December 11, 2025) discloses compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo using non-viral delivery of polynucleotides encoding transcription factors. The patent application is now publicly available.

Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3

USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.

Peptide Analogue for Treatment of Diabetes or Obesity

USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.

Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment

USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.

Methods for Treating Fatty Liver Disease (NASH) with Resmetirom

USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.

Arixtra Recall: Needle Iron Particle Discoloration in Pre-filled Syringes

BfArM issued a Drug Safety Communication regarding Viatris Healthcare Limited's Arixtra (fondaparinux sodium) pre-filled syringes. Reports indicate brown discoloration and blockage in needles caused by oxidized iron particles. Affected batches must not be dispensed or administered if discoloration is observed.

Phenhydan Injection: DHPC on Visual Particles, Filter Required

BfArM published an updated DHPC from Desitin Arzneimittel GmbH regarding Phenhydan solution for injection (phenytoin sodium), following particle contamination identified in batch 021950 during official sample analysis. The company clarified that a syringe filter with 0.2-0.45 µm pore size must be used when drawing up the solution, then removed before patient administration. This supersedes the November 2025 filter guidance which was corrected for accuracy.

Accupaque Visipaque Batch Risk Alert: Particle Contamination in Iohexol Iodixanol Solutions

GE Healthcare Buchler GmbH & Co. KG issued a Direct Healthcare Professional Communication (DHPC) alerting to a potential risk of particles in certain batches of Accupaque (iohexol) and Visipaque (iodixanol) solutions for injection filled into polypropylene bottles. The company instructs that only clear, particle-free solutions may be used per the Summary of Product Characteristics (SmPC), and this must be verified prior to administration.

Eberth Antibiotics - Outdated Package Inserts Create Patient Safety Risk

Dr. Friedrich Eberth Arzneimittel GmbH issued a Direct Healthcare Professional Communication (DHPC) via BfArM alerting that certain batches of nine antibiotic and antifungal products have outdated package inserts, creating a potential patient safety risk. Affected products include multiple strengths of cefazolin, cefotaxime, ceftazidime, ceftriaxone, levofloxacin, moxifloxacin, and voriconazole. Healthcare professionals are advised to discard outdated package inserts and refer to the current package inserts provided with the communication.

Mysimba Cardiovascular Risk and Annual Assessment Requirements

BfArM, in agreement with EMA, issued a Direct Healthcare Professional Communication regarding Mysimba (naltrexone/bupropion). The communication addresses long-term cardiovascular risks that have not been fully determined for patients treated beyond one year. New recommendations include discontinuation of treatment after one year if patients have not maintained at least 5% weight loss, and mandatory annual cardiovascular risk assessments for treatment continuation decisions.

ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.

HIV/HBV Treatment Using CD8-Targeting Fusion Proteins

USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.